Management of Hepatocellular Carcinoma: Future Directions in Care
Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.
Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line
Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.
Treatment Options for Advanced HCC in the Second-Line and Beyond
Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.
Novel First-Line Immunotherapy Approaches in Advanced HCC
Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.
Real-World Use of Durvalumab + Tremelimumab in Advanced HCC
In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.
Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab
Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.
Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC
Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.
Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options
Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.
Selecting the Appropriate First-Line Therapy for Advanced HCC
In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.
Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib
Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.
Advanced HCC: Updates in First-line Systemic Therapy
Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.
Role of Systemic Therapy in Early- or Intermediate-Stage HCC
Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.
Role of Locoregional Therapy in Early- or Intermediate-Stage HCC
Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.
Early- and Intermediate-Stage HCC Treatment Landscape
Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.
Future Directions for HCC Management
Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.
Management of Advanced HCC Associated With NASH
Stephen L. Chan, MD, leads the discussion on the prevalence and management of advanced HCC in patients with NASH.
Treatment Options for Advanced HCC With Underlying NASH
A panel of experts in gastroenterology review the case of a 65-year-old man with advanced HCC associated with NASH and comment on treatment with TKIs and immunotherapy.
Sequencing Systemic Therapy for Advanced HCC
Andrea Casadei Gardini, MD, leads the discussion on the optimal sequencing of systemic therapy for advanced HCC.
Optimizing the Selection of Frontline TKIs for Advanced HCC
Experts in gastroenterology share their approaches to first-line single-agent and combination TKI therapies for the treatment of advanced HCC.
Updates to First-line Treatment Options for Advanced HCC
Andrea Casadei Gardini, MD, presents the case of a 63-year-old man diagnosed with advanced HCC, and the panel reviews available first-line treatment options for patients with advanced HCC.
Is There a Role for Systemic Therapy for Patients With Intermediate HCC?
Gastroenterology experts discuss whether there a is a role for systemic therapy for the management of intermediate HCC.
Role of TACE and TARE in the Treatment of HCC
Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.
Updates to Adjuvant and Neoadjuvant Therapy in Early HCC
Stephen L. Chan, MD, reviews the case of a 72-year-old woman with mild alcoholic cirrhosis and provides insight on the potential role of adjuvant and neoadjuvant therapy for the treatment of HCC.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512